S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Buy THIS stock before Taiwan is attacked (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Buy THIS stock before Taiwan is attacked (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Buy THIS stock before Taiwan is attacked (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Buy THIS stock before Taiwan is attacked (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
NASDAQ:ACHL

Achilles Therapeutics - ACHL Stock Forecast, Price & News

$0.88
+0.03 (+3.53%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.86
$0.90
50-Day Range
$0.84
$1.26
52-Week Range
$0.75
$3.45
Volume
90,240 shs
Average Volume
383,808 shs
Market Capitalization
$36.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Achilles Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,036.5% Upside
$10.00 Price Target
Short Interest
Healthy
0.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Achilles Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.79) to ($1.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

228th out of 995 stocks

Biological Products, Except Diagnostic Industry

39th out of 166 stocks


ACHL stock logo

About Achilles Therapeutics (NASDAQ:ACHL) Stock

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACHL Stock News Headlines

Gerard Achilles M. Obnial
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Achilles Therapeutics PLC
Achilles Therapeutics PLC ADR - Stock Quote ACHL
See More Headlines
Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACHL Company Calendar

Last Earnings
11/08/2021
Today
3/27/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACHL
Fax
N/A
Employees
242
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+809.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-71,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.03 per share

Miscellaneous

Free Float
38,736,000
Market Cap
$36.02 million
Optionable
Not Optionable
Beta
0.98

Key Executives

  • Dr. Iraj Ali (Age 46)
    CEO & Director
  • Dr. Karl Peggs M.D. (Age 55)
    Founder & Chief Medical Officer
  • Dr. Mark William Lowdell BSc (Age 59)
    FRCPath, MICR, MSc, Ph.D., Founder
  • Dr. Charles Swanton FMEDSCI (Age 49)
    M.D., Ph.D., Founder
  • Dr. Sergio A. Quezada Ph.D. (Age 46)
    Founder & Chief Scientific Officer
  • Mr. Robert Coutts (Age 38)
    Chief Financial Officer
  • Mr. Lee M. Stern
    VP of Investor Relations & External Communications
  • Mr. Daniel Hood
    Gen. Counsel & Company Sec.
  • Julia Wilson
    Head of Communications
  • Mr. Tariq Ahmed
    VP of People













ACHL Stock - Frequently Asked Questions

Should I buy or sell Achilles Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHL shares.
View ACHL analyst ratings
or view top-rated stocks.

What is Achilles Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 1 year price objectives for Achilles Therapeutics' shares. Their ACHL share price forecasts range from $8.00 to $12.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,036.5% from the stock's current price.
View analysts price targets for ACHL
or view top-rated stocks among Wall Street analysts.

How have ACHL shares performed in 2023?

Achilles Therapeutics' stock was trading at $0.90 at the beginning of 2023. Since then, ACHL shares have decreased by 2.2% and is now trading at $0.8799.
View the best growth stocks for 2023 here
.

Are investors shorting Achilles Therapeutics?

Achilles Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 6,300 shares, a drop of 33.7% from the February 28th total of 9,500 shares. Based on an average daily volume of 445,400 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company's stock are sold short.
View Achilles Therapeutics' Short Interest
.

When is Achilles Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ACHL earnings forecast
.

How were Achilles Therapeutics' earnings last quarter?

Achilles Therapeutics plc (NASDAQ:ACHL) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.14.

When did Achilles Therapeutics IPO?

(ACHL) raised $176 million in an initial public offering on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO.

What is Achilles Therapeutics' stock symbol?

Achilles Therapeutics trades on the NASDAQ under the ticker symbol "ACHL."

Who are Achilles Therapeutics' major shareholders?

Achilles Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (4.11%), Point72 Asset Management L.P. (3.61%), Renaissance Technologies LLC (1.24%), Millennium Management LLC (0.21%), Jane Street Group LLC (0.12%) and Virtu Financial LLC (0.08%).

How do I buy shares of Achilles Therapeutics?

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achilles Therapeutics' stock price today?

One share of ACHL stock can currently be purchased for approximately $0.88.

How much money does Achilles Therapeutics make?

Achilles Therapeutics (NASDAQ:ACHL) has a market capitalization of $36.02 million. The company earns $-71,180,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis.

How many employees does Achilles Therapeutics have?

The company employs 242 workers across the globe.

How can I contact Achilles Therapeutics?

Achilles Therapeutics' mailing address is 245 HAMMERSMITH ROAD, LONDON X0, W6 8PW. The official website for the company is www.achillestx.com. The company can be reached via phone at 44-0-20-8154-4600 or via email at ir@achillestx.com.

This page (NASDAQ:ACHL) was last updated on 3/28/2023 by MarketBeat.com Staff